WO2001040455A2 - Compositions et procedes servant a augmenter l'encapsidation et la production d'adenovirus de recombinaison au moyen de signaux multiples d'encapsidation - Google Patents

Compositions et procedes servant a augmenter l'encapsidation et la production d'adenovirus de recombinaison au moyen de signaux multiples d'encapsidation Download PDF

Info

Publication number
WO2001040455A2
WO2001040455A2 PCT/US2000/032235 US0032235W WO0140455A2 WO 2001040455 A2 WO2001040455 A2 WO 2001040455A2 US 0032235 W US0032235 W US 0032235W WO 0140455 A2 WO0140455 A2 WO 0140455A2
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviral
packaging
adenovirus
recombinant
vector
Prior art date
Application number
PCT/US2000/032235
Other languages
English (en)
Other versions
WO2001040455A3 (fr
Inventor
Guangping Gao
James M. Wilson
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to JP2001542523A priority Critical patent/JP2003523180A/ja
Priority to CA002392537A priority patent/CA2392537A1/fr
Priority to AU17968/01A priority patent/AU1796801A/en
Priority to EP00980747A priority patent/EP1234048A2/fr
Priority to US10/169,544 priority patent/US6821512B1/en
Publication of WO2001040455A2 publication Critical patent/WO2001040455A2/fr
Publication of WO2001040455A3 publication Critical patent/WO2001040455A3/fr
Priority to US10/996,341 priority patent/US20070134203A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the invention relates generally to the field of adenoviral vectors useful in delivering genes and methods of producing same.
  • Adenoviruses have been described as useful viral vectors for delivery of therapeutic genes into selected host cells. Due to interest in adenoviruses as delivery vehicles, several groups have investigated the mechanisms that allow selective packaging of the adenovirus (Ad) genome into viral capsids.
  • Ad5 packaging domain Within the left end of the Ad genome, a cis-ac ng packaging domain has been identified [M. Grable and P. Hearing, J. Virol. £4:2047-2056 (May 1990)]. Mutants of Ad serotype 5 (Ad5) lacking this region are nonviable but can be rescued by insertion of the left-terminal 355 nt at the right end of the viral genome.
  • the Ad5 packaging domain has been found to function in an inverted orientation, and can be moved within several hundred base pairs from its original location without a reduction in virus yield [P. Hearing et al, J. Virol..61:2555-2558 (Aug. 1987)].
  • the Ad5 packaging domain consists of at least seven elements which are functionally redundant.
  • a repeat I is located within nt 240- 248; A repeat II is located within nt 260-268; A repeat III is located within nt 302- 311; A repeat IV is located within nt 313-321; A repeat V is located within nt 337- 346; A repeat VI is located within nt 363 and 368 of Ad5; A repeat VII is located within nt 370-375 of Ad5 [M. Grable and P. Hearing, J. Virol, 66(2):723-731 (Feb.
  • the present invention provides compositions and methods useful for efficiently packaging recombinant adenoviruses and producing high yields thereof.
  • the invention involves engineering recombinant adenoviruses to contain multiple functional adenoviral packaging domains.
  • these vectors contain at least five of the "A" repeat elements of the adenoviral packaging domains, in duplicate.
  • the vectors contain at least one intact adenoviral packaging domain and a second adenoviral packaging domain containing at least five "A" repeat elements.
  • the invention provides (a) an adenovirus 5' inverted terminal repeat, (b) a first adenovirus packaging domain, (c) a second adenovirus packaging domain; (d) a selected transgene under the control of regulatory sequences directing expression of the transgene, and (3) a 3' inverted terminal repeat.
  • the second packaging domain is located 5' to the native El region and the selected transgene.
  • the invention provides a pharmaceutical composition comprising a recombinant adenovirus of the invention and a physiologically compatible carrier.
  • the invention provides a method of delivering a transgene to a selected host cell by infecting said cell with a recombinant adenovirus of the invention.
  • the invention provides a method of increasing the packaging and yield of a selected recombinant adenovirus.
  • the method involves engineering the selected recombinant adenovirus vector to contain at least two adenoviral packaging domains.
  • the invention provides a method of producing a recombinant adenovirus which lacks functional adenoviral early, intermediate and late genes.
  • the method involves co-culturing in a host cell (a) a recombinant adenoviral plasmid comprising multiple adenoviral packaging domains and a selected transgene, said plasmid lacking functional adenoviral early, intermediate and late genes; and (b) a helper virus.
  • the rAd plasmids and helper virus together with the host cell, provide sufficient adenoviral gene functions to permit packaging of the recombinant adenoviral plasmid into an adenoviral capsid.
  • the present invention provides an adenoviral vector which comprises at least two adenoviral packaging domains, as defined herein. These vectors are characterized by enhanced packaging ability and yield, as compared to viral vectors containing native packaging signals. Thus, the invention provides compositions and methods which have significant advantages in the production of recombinant adenoviral vectors.
  • the recombinant adenoviral vectors of the invention are composed of, at a minimum, adenovirus 5' inverted terminal repeat sequences (ITRs), a first adenovirus packaging domain, a second adenovirus packaging domain, a selected transgene, and an adenovirus 3' ITR.
  • ITRs inverted terminal repeat sequences
  • the term vector includes, without limitation, any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc.
  • the DNA sequences providing the adenoviral elements and encoding the adenovirus genes useful in this invention may be selected from among any known adenovirus type, including the presently identified 41 human types [see, e.g., Horwitz, cited above]. Similarly, adenoviruses known to infect other animals may supply the gene sequences. The selection of the adenovirus type for each adenoviral element or gene sequence does not limit this invention.
  • the sequences for a number of adenovirus (Ad) serotypes, including that of Ad serotype 5, are available from the GenBank database.
  • Adenoviral ITRs are available from the American Type Culture Collection, Manassas, Virginia, or are available by request from a variety of commercial and institutional sources.
  • the adenovirus sequences used in the vectors of the invention may be derived from one or more wild-type adenoviruses or mutant adenoviruses.
  • A. Adenoviral ITRs are available from the American Type Culture Collection, Manassas, Virginia, or are available by request from a variety of commercial and institutional sources.
  • the adenovirus sequences used in the vectors of the invention may be derived from one or more wild-type adenoviruses or mutant adenoviruses.
  • the 5' and 3' adenoviral inverted terminal repeats are located at the extreme 5' and extreme 3' ends of the adenoviral genome, respectively.
  • the 5' and 3' ITRs are similarly located at or near the extreme termini of the recombinant adenoviral vectors of the invention.
  • These ITRs may be obtained from any of the adenoviral serotypes described above, or may be artificial sequences, e.g., synthetic or mutated sequences that have the same or equivalent packaging functions as native ITRs.
  • adenovirus packaging domain refers to the nucleic acid sequences of the adenoviral repeat elements required to package an adenoviral vector into a capsid protein.
  • the packaging domain of the Ad5 is among the best studied of the human serotypes [see, Grable and Hearing (1992), cited above], this invention is not so limited.
  • the repeat sequences of other adenoviral serotypes may be readily substituted in the present invention. Further, one of skill in the art may substitute functional fragments of one or more of the A repeat sequences. Additionally, the repeat elements and/or their functional fragments may be produced synthetically using conventional methods.
  • additional sequences may be included in the adenoviral packaging domains used in the vectors of the invention.
  • adenoviral packaging domain used in the vectors of the invention.
  • the adenovirus sequences of the packaging domain may extend 3' and/or 5' beyond the functional repeat elements.
  • one suitable adenovirus packaging domain may contain nt 218-354 of Ad5 which encompasses repeats I-V.
  • a suitable adenovirus packaging domain may contain nt 186-371 which encompasses repeats I - VI and contains a partial repeat NIL
  • the adenoviral packaging domains may further contain other sequences which serve to separate the individual repeat elements and/or the 5' ITRs from the repeats of the adenoviral packaging domain and/or which serve to separate the multiple adenoviral packaging domains.
  • sequences may be from 5 bp to 200 bp, 10 bp to 100 bp, 20 bp to 60 bp, or 30 bp to 50 bp in length.
  • the length of these sequences may be readily adjusted as needed for convenience.
  • These sequences may be viral in nature, or may obtained from other recombinant or synthetic means, and do not significantly impair the packaging function of the adenoviral packaging domain.
  • the adenoviral vectors of the invention contain multiple packaging domains (i.e., at least two packaging domains, and optionally three, four, five, six or more).
  • the adenoviral vectors contain a first adenoviral packaging domain which contains A repeat elements I through N and a second adenoviral packaging domain.
  • the second adenoviral packaging domain contains at least five A repeat elements, and most preferably, A repeat elements I through V.
  • the second adenoviral packaging domain is not so limited and one of skill in the art may readily design the adenoviral vector such that the second adenoviral packaging domain contains as few as two, three or four of the A repeat element selected from I through VII).
  • the first adenoviral packaging domain contains A repeat elements I through VII and the second adenoviral packaging domain contains at least A repeat elements I through V.
  • the vector contains two packaging domains of nt 240-346, together with the other vector elements.
  • an adenoviral vector contains a first packaging domain of nt 240-375 (repeats I- VII) and a second packaging domain of nt 240-346 (repeats I-V), together with the other vector elements.
  • An adenoviral vector of the invention may contain multiple copies of selected repeat elements located directly after one another, but located within one complete adenoviral packaging domain.
  • an adenoviral vector of the invention may contain the sequences encompassing repeats I-V, a second packaging domain encompassing repeats I-V, followed by the sequences encompassing repeats VI and NIL
  • an adenoviral vector of the invention may contain the sequences encompassing repeats I-NI, a second packaging domain encompassing repeats I-NI, following the sequences encompassing repeat NIL
  • the adenoviral vector of the invention may contain the multiple packaging domains located in tandem.
  • an adenoviral vector of the invention may contain the sequences encompassing repeats I-NII followed by the sequences encompassing repeats I-N.
  • both the first and second adenoviral packaging domains are located within 100 to 400 bp from the left terminus of the adenoviral vector and 5' to the El sequences, if the El sequences are intact.
  • the first and second adenoviral packaging domains are preferably located within map units 0-1 of the adenoviral genome.
  • the first and second adenoviral packaging domains are located 5' to the transgene sequences.
  • At least one of the adenoviral packaging domains is located in its native location, i.e., 3' to the adenoviral 5' ITR sequences and no more than 375 bp from the left terminus of the adenoviral vector.
  • the 5' ITRs and a first adenoviral packaging domain are both present in their native locations and the second adenoviral packaging domain is engineered to be no more than 20 to 200 bp 3' from the first adenoviral packaging domain.
  • the adenoviral packaging domains may be present in the constructs of the invention in either standard orientation or inverted orientation.
  • at least two of the multiple adenoviral packaging domains are in the same orientation.
  • the adenoviral vectors and viruses of the invention are useful for delivery of genes to host cells for a variety of purposes, which include both therapeutic and vaccinal uses. Because the adenoviral packaging domains are relatively small (i.e., in the range of about 100-190 bp) and recombinant adenoviral capsids can package vectors of up to 105% of the size of the native adenoviral genome (-36 kb), it is not necessary to delete any adenoviral genes to accommodate the second adenoviral packaging domain. Consequently, a second adenoviral packaging domain may be engineered 5' to the El region, even if the El genes are present in the vector.
  • the present invention is not limited by the adenoviral genes which are present in the vector and may contain a minimal deletion (e.g., where only those adenoviral sequences are absent which are necessary for insertion of the sequences which encode the product to be expressed in the host cell) or may contain a functional deletion of one or all adenovirus genes.
  • a recombinant adenoviral vector of the invention containing multiple adenoviral packaging domains, and other suitable adenoviral elements, as needed or desired.
  • “functional fragment” is that region of coding sequence or gene product which is required to provide the necessary or desired function.
  • nucleic acid sequence e.g., a gene
  • functional deletions of adenoviral sequences the invention further encompasses deletions of adenoviral sequences which do not extinguish a desired gene function.
  • a suitable "non-functional" deletion may encompass a deletion of all of the E4 sequences except those sequences which encode the E4 ORF6 gene product.
  • the adenoviral vector of the invention is rendered replication-defective by the absence of functional El genes (such a virus can not replicate in the absence of an external source of the necessary El gene products, Ela and Elb).
  • the ⁇ Ad vector An exemplary vector containing only the minimal adenoviral sequences is termed the ⁇ Ad vector.
  • This vector lacks all functional adenoviral genes including El, E2, E3, E4, intermediate gene IX, IXa and late genes LI, L2, L2, L4 and L5.
  • the adenoviral vector contains, in addition to the multiple packaging domains and minimal adenoviral sequences described above, functional adenoviral E2, E4, and IX genes.
  • the adenoviral sequences in the adenoviral vector include the 5' and 3' cis-elements, the multiple packaging domains, functional E2 and E4 genes, intermediate genes IX and IXa, and late genes LI through L5.
  • the adenoviral vector may be readily engineered by one of skill in the art, taking into consideration the minimum sequences required, and is not limited to these exemplary embodiments.
  • the IX sequences are supplied in trans by a helper virus.
  • the transgene is operatively linked to regulatory components of the vector in a manner which permits transgene transcription.
  • the transgene sequence is a nucleic acid sequence, heterologous to the
  • Ad sequence which encodes a polypeptide or protein of interest.
  • the transgene is a nucleic acid sequence, heterologous to the adenovirus sequence, which encodes a polypeptide, protein, or other product, of interest.
  • the composition of the transgene sequence depends upon the intended use for the resulting rAd of the invention.
  • one type of transgene sequence comprises a reporter or marker sequence which, upon expression, produces a detectable signal.
  • reporter or marker sequences include, without limitation, DNA sequences encoding ⁇ -lactamase, ⁇ - galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, membrane bound proteins including, for example, CD2, CD4, CD8, and the influenza hemagglutinin protein, as well as others well known in the art.
  • high affinity antibodies to such proteins exist or can be made routinely, as can fusion proteins comprising a membrane bound protein appropriately fused to an antigen tag domain from, among others, hemagglutinin or Myc.
  • sequences when associated with regulatory elements which drive their expression, provide signals detectable by conventional means.
  • conventional means include enzymatic, radiographic, colorimetric, fluorescence or other spectrographic assays, fluorescent activated cell sorting assay and immunological assays, including ELISA, RIA and immunohistochemistry.
  • the transgene is the LacZ gene
  • the presence of rAd is detected by assays for beta-galactosidase activity.
  • rAd may be measured by light production in a luminometer.
  • the transgene is a non-marker gene which can be delivered to a cell or an animal via the rAd of the invention.
  • the transgene may be selected from a wide variety of gene products useful in biology and medicine, such as proteins, antisense nucleic acids (e.g., RNAs), or catalytic RNAs.
  • the rAd of the invention are useful for delivery of gene products which induce an immune response, e.g., for vaccine purposes.
  • Suitable gene products may be readily selected by one of skill in the art from among immunogenic proteins and polypeptides derived from viruses, as well as from prokaryotic and eukaryotic organisms, including unicellular and multicellular parasites.
  • the rAd of the invention are useful for delivery of a transgene which encodes any product desirable for study.
  • the selection of the transgene sequence is not a limitation of this invention. Choice of a transgene sequence is within the skill of the artisan in accordance with the teachings of this application.
  • the rAd vectors of the invention are useful for correcting or ameliorating gene deficiencies, wherein normal genes are expressed but at less than normal levels.
  • the rAd vectors may also be used to correct or ameliorate genetic defects wherein a functional gene product is not expressed.
  • a preferred type of transgene sequence is a therapeutic gene which expresses a desired gene product in a host cell.
  • the invention includes methods of producing a rAd vector which can be used to correct or ameliorate a gene defect caused by a multi-subunit protein.
  • a different transgene may be used to encode each subunit of the protein. This is desirable when the size of the DNA encoding the protein subunit is large, e.g., for an immunoglobulin or the platelet-derived growth factor receptor.
  • a cell would be infected with rAd containing each of the different subunits.
  • different subunits of a protein may be encoded by the same transgene.
  • a single transgene would include the DNA encoding each of the subunits, with the DNA for each subunit separated by an internal ribosome entry site (IRES).
  • IRES internal ribosome entry site
  • Useful gene products include hormones and growth and differentiation factors including, without limitation, insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (NEGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factors (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor ⁇ (TGF ⁇ ), platelet-derived growth factor (PDGF), insulin-like growth factors I and II (IGF-I and IGF-II), any one of the transforming growth factor ⁇ (TGF ⁇ ) superfamily comprising TGF ⁇ , activins, inhibins, or any of the bone morphogenic proteins
  • cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL) IL-l ⁇ , IL-l ⁇ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, and IL-17, monocyte chemoattractant protein (MCP-1), leukemia inhibitory factor (LIF), granulocyte-macrophage colony stimulating factor (GM-CSF), Fas ligand, tumor necrosis factors ⁇ and ⁇ (TNF ⁇ and TNF ⁇ ), interferons (IFN) IFN- ⁇ , IFN- ⁇ and IFN- ⁇ , stem cell factor, flk-2/flt3 ligand.
  • TPO thrombopoietin
  • IL interleukins
  • IL-2 interleukins
  • IL-2 inter
  • Gene products produced by the immune system are also encompassed by this invention. These include, without limitations, immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II MHC molecules, as well as engineered MHC molecules including single chain MHC molecules.
  • Useful gene products also include complement regulatory proteins such as membrane cofactor protein (MCP), decay accelerating factor (DAF), CR1, CR2 and CD59.
  • Still other useful gene products include any one of the receptors for the hormones, growth factors, cytokines, lymphokines, regulatory proteins and immune system proteins.
  • the invention encompasses receptors for cholesterol regulation, including the LDL receptor, HDL receptor, VLDL receptor, and the scavenger receptor.
  • the invention also encompasses gene products such as the steroid hormone receptor superfamily including glucocorticoid receptors and estrogen receptors, Nitamin D receptors and other nuclear receptors.
  • useful gene products include transcription factors such as jun,fos, max, mad, serum response factor (SRF), AP-1, AP-2, myh, MRG1, CREM, Alx4, FREAC1, NF- ⁇ B, members of the leucine zipper family, C2H4 zinc finger proteins, including Zif268, EGR1, EGR2, C6 zinc finger proteins, including the glucocorticoid and estrogen receptors, POU domain proteins, exemplified by Pitl, homeodomain proteins, including HOX-1, basic helix- loop-helix proteins, including myc, MyoD and myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C/EBP, SP1, CCAAT-box binding proteins, interferon regulation factor 1 (IRF-1), Wilms tumor protein, ETS-binding protein, STAT, GATA-box binding proteins, e.g., GATA,
  • Other useful gene products include carbamoyl synthetase I, ornithine transcarbamylase, arginosuccinate synthetase, arginosuccinate lyase, arginase, fumarylacetoacetate hydrolase, phenylalanine hydroxylase, alpha- 1 antitrypsin, glucose-6-phosphatase, low-density-lipoprotein receptor, porphobilinogen deaminase, factor VIII, factor IX, cystathione beta-synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, beta-glucosidase, pyruvate carboxylase, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase
  • transgenes include non-naturally occurring polypeptides, such as chimeric or hybrid polypeptides or polypeptides having a non-naturally occurring amino acid sequence containing insertions, deletions or amino acid substitutions.
  • polypeptides such as chimeric or hybrid polypeptides or polypeptides having a non-naturally occurring amino acid sequence containing insertions, deletions or amino acid substitutions.
  • single-chain engineered immunoglobulins could be useful in certain immunocompromised patients.
  • Other types of non-naturally occurring gene sequences include antisense molecules and catalytic nucleic acids, such as ribozymes, which could be used to reduce overexpression of a gene.
  • Design of the transgene for expression in mammalian cells and hosts should include appropriate sequences that are operably linked to the gene of interest to promote its expression.
  • "Operably linked" sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. Such expression control sequences are discussed in more detail in connection with the transgene.
  • Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion.
  • expression control sequences native, constitutive, inducible and/or tissue-specific — are known in the art and may be utilized to drive expression of the transgene, depending upon the type of expression desired.
  • expression control sequences typically include a promoter, an enhancer, such as one derived from an immunoglobulin gene, SV40, cytomegalovirus, etc., and a polyadenylation sequence which may include splice donor and acceptor sites.
  • the polyadenylation sequence generally is inserted following the transgene sequences and before the 3' Ad ITR sequence.
  • a rAd vector of the present invention may also contain an intron, desirably located between the promoter/enhancer sequence and the transgene.
  • IRES internal ribosome entry site
  • An IRES sequence is used to produce more than one polypeptide from a single gene transcript.
  • An IRES sequence would be used to produce a protein that contains more than one polypeptide chains. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein at, for example, pages 3.18-3.26 and 16.17-16.27 and Ausubel et al., Current Protocols in Molecular Biology. John Wiley & Sons, New York, 1989].
  • high-level constitutive expression will be desired.
  • promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the S O promoter, the dihydrofolate reductase promoter, the ⁇ - actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFl ⁇ promoter [Invitrogen].
  • RSV Rous sarcoma virus
  • CMV cytomegalovirus
  • Inducible promoters are regulated by exogenously supplied compounds, including, the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system [WO 98/10088]; the ecdysone insect promoter [No et al, Proc. Natl. Acad. Sci. USA. 92:3346-3351 (1996)], the tetracycline- repressible system [Gossen et al, Proc. Natl. Acad. Sci. USA.
  • inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
  • the native promoter for the transgene will be used.
  • the native promoter may be preferred when it is desired that expression of the transgene should mimic the native expression.
  • the native promoter may be used when expression of the transgene must be regulated temporally or developmentally, or in a tissue-specific manner, or in response to specific transcriptional stimuli.
  • other native expression control elements such as enhancer elements, polyadenylation sites or Kozak consensus sequences may also be used to mimic the native expression.
  • Another embodiment of the transgene includes a transgene operably linked to a tissue-specific promoter. For instance, if expression in skeletal muscle is desired, a promoter active in muscle should be used.
  • tissue-specific are known for liver [albumin, Miyatake et al. J. Virol., 71 :5124-32 (1997); hepatitis B virus core promoter, Sandig et al., Gene Ther.. 3.1002-9 (1996); alpha-fetoprotein (AFP), Arbuthnot et al., Hum. Gene Ther.
  • Suitable promoter/enhancer sequences may be selected by one of skill in the art using the guidance provided by this application. Such selection is a routine matter and is not a limitation of the molecule or construct. For instance, one may select one or more expression control sequences, operably link the sequence to a transgene of interest, and insert the "minigene" comprising the expression control sequence and the transgene into an Ad vector.
  • RNA expression may be monitored by Northern blotting or quantitative RT-PCR.
  • protein expression may be monitored by Western blotting, immunohistochemistry, ELISA, RIA, or tests of the transgene's gene product's biological activity.
  • one may easily assay whether a particular expression control sequence is suitable for a specific transgene, and choose the expression control sequence most appropriate for expression of the desired transgene.
  • adenoviral vectors and other nucleic acid molecules of the invention may be transferred to a host cell for packaging into a viral capsid by any suitable method.
  • suitable methods include, for example, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA- coated pellets, viral infection and protoplast fusion. Thereafter, cells are cultured according to standard methods.
  • the mammalian host cell itself may be selected from any mammalian species, such as human cell types, including, without limitation, cells such as CHO, BKH, MDCK, and various murine cells, e.g., 10T1/2 and WEHI cells, African green monkey cells such as VERO, COSl, COS7, BSCl, BSC 40, and BMT 10, and human cells such as WI38, MRC5, A549, human embryonic retinoblast (HER), human embryonic kidney (HEK), human embryonic lung (HEL), and TH1080 cells.
  • human cell types including, without limitation, cells such as CHO, BKH, MDCK, and various murine cells, e.g., 10T1/2 and WEHI cells, African green monkey cells such as VERO, COSl, COS7, BSCl, BSC 40, and BMT 10, and human cells such as WI38, MRC5, A549, human embryonic retinoblast (HER), human embryonic kidney (HEK), human embryonic lung (
  • appropriate cells include 293 cells (human embryonic kidney cells which express adenoviral Ela and Elb proteins), 91 1, PER.C6 cells (human embryonic retinoblast cells that express adenoviral El; see WO 97/19463), GH329 cells (a cell line that expresses adenoviral El); 27-18 cells, 84-31 cells (293-based cells that express adenovirus Ela, Elb and E4 [G. Gao, J. Virol., 70(12):8934-8943 (1996)], 10-3 cells (293-based cells that express adenovirus Ela, Elb and E4ORF6 [G. Gao, J. Virol.
  • 3T3 cells mouse embryonic fibroblast cell line
  • NIH3T3 cells subline of 3T3 cells
  • HepG2 cells human liver carcinoma cell line
  • Saos-2 cells human osteogenic sarcomas cell line
  • HuH7 cells human carcinoma cell line
  • the vector is introduced into and cultured in E 1 -complementing cells using conventional techniques, such as the transfection techniques known in the art [see, K. Kozarsky et al, Som. Cell and Molec. Genet., 12(5):449-458 (1993)]. Thereafter, recombinant adenoviruses are isolated and purified following transfection.
  • these adenovirus genes are supplied by a helper virus, a packaging cell, or a combination thereof.
  • the vector may be packaged into a viral capsid by culturing the cell in an El/E4-complementing cell line (e.g., 84-31, 27-18, or 10-3 cells).
  • the vector may be packaged by culturing the cell in an El -complementing cell line in the presence of a helper virus which supplies the E4 function.
  • other recombinant vectors of the invention which contain a functional deletion in an adenoviral gene may be packaged in a selected host cell, optionally in the presence of a helper virus where the host cell does not supply all necessary adenovirus gene functions.
  • helper virus is required for production.
  • the separation of a desired packaged recombinant adenovirus from a culture also containing helper virus has long been a problem which has existed in the art. For example, if the recombinant vector of the invention contains functional deletions of all adenoviral genes, a helper virus is required to supply the adenoviral gene IX function and the function of any adenoviral genes not provided by the host cell.
  • the host cell line is an El -complementing cell line (e.g., 293 cells) and the helper virus provides the E2, E3, E4, intermediate gene IXa and late genes L1-L5.
  • the compositions of the present invention provide a significant advantage in production of such a deleted adenovirus over prior art methods.
  • the recombinant adenoviruses of the invention have an advantage in packaging and growth over other recombinant adenoviruses.
  • the recombinant adenoviruses of the invention significantly outgrow the helper virus used in this production method.
  • the recombinant adenovirus vectors of the invention may be readily purified from culture using methods well l nown to those of skill in the art.
  • the helper viruses may be removed from the culture using any of a variety of known systems including the Cre-Lox system [See, WO 98/10086], a restriction enzyme system [International Patent Application No. PCT/US00/00415, filed January 7, 2000, for "Compositions and Methods Useful for Production of Recombinant Viruses Which Require Helper Viruses"].
  • the viruses may be subjected to plaque purification and the lysates subjected to cesium chloride centrifugation to obtain purified virus.
  • the cells are subjected to two to three rounds of freeze-thawing.
  • the resulting lysate is subjected to centrifugation for collection, and the supernatant is collected.
  • adenoviruses are suitable for a variety of uses in vitro, ex vivo and in vivo.
  • the recombinant adenovirus vectors of the invention may be used to deliver a selected transgene to a host cell by any suitable means.
  • the vectors and the cells are mixed in vitro and the infected cells are cultured using conventional methodologies.
  • the recombinant adenovirus vectors may be administered to a human or non-human mammalian patient.
  • suitable carriers may be readily selected by one of skill in the art in view of the indication to which the vector is directed, e.g., whether therapeutic or vaccinal.
  • one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline).
  • Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water.
  • compositions of the invention may contain, in addition to the recombinant adenovirus vectors and carriers, other conventional pharmaceutical ingredients, such as preservatives, chemical stabilizers, or for vaccine use, adjuvants.
  • suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.
  • Suitable chemical stabilizers include gelatin and albumin.
  • Suitable exemplary adjuvants include, among others, immune-stimulating complexes (ISCOMS), LPS analogs including 3-O-deacylated monophosphoryl lipid A (Ribi Immunochem Research, Inc.; Hamilton, MT), mineral oil and water, aluminum hydroxide, Amphigen, Avirdine, L121/squalene, muramyl peptides, and saponins, such as Quil A.
  • ISCOMS immune-stimulating complexes
  • LPS analogs including 3-O-deacylated monophosphoryl lipid A (Ribi Immunochem Research, Inc.; Hamilton, MT), mineral oil and water, aluminum hydroxide, Amphigen, Avirdine, L121/squalene, muramyl peptides, and saponins, such as Quil A.
  • Any suitable route of administration may be used, including, direct delivery to the target organ, tissue or site, intranasal, intravenous, intramuscular, subcutaneous, intradermal and oral administration. Routes of administration may be combined within the course of repeated therapy or immunization.
  • adenoviruses have been deemed suitable for applications in which transient transgene expression is therapeutic (e.g., p53 gene transfer in cancer and VEGF gene transfer in heart diseases).
  • the adenoviruses are not limited to use where transient transgene expression is desired.
  • the adenoviruses are useful for a variety of situations in which delivery and expression of a selected transgene is desired.
  • Suitable doses of El -deleted adenoviruses may be readily determined by one of skill in the art, depending upon the condition being treated, the health, age and weight of the veterinary or human patient, and other related factors. However, generally, a suitable dose may be in the range of 10 10 to 10 18 , and preferably about 10 13 to 10 16 viral particles per dose, for an adult human having weight of about 80 kg. This dose may be suspended in about 0.01 mL to about 1 mL of a physiologically compatible carrier and delivered by any suitable means. The dose may be repeated, as needed or desired, daily, weekly, monthly, or at other selected intervals.
  • the recombinant adenovirus vectors of the invention which contain multiple adenoviral packaging domains, are useful for any of the variety of gene delivery applications known in the art for conventional adenoviral vectors.
  • these recombinant adenoviruses of the invention provide significant advantages in that the constructs of the invention have improved packaging and generate higher yields of the recombinant adenoviruses, as compared to conventional adenoviral vectors.
  • Recombinant adenoviruses are created in El -complementing cells through homologous recombination between a plasmid shuttle vector and an Ad5 viral backbone with a deletion in the El region.
  • duplicate adenovirus packaging domains To generate the duplicate adenovirus packaging domains, conventional polymerase chain reaction techniques can be used, followed by confirmation by sequencing that the insert is correct. Alternatively, duplicate adenovirus packaging domains may be generated using molecular cloning techniques.
  • the following examples create a cloning vector from viral isolates of H5.001CBhOTC which have either (a) Ad 5' ITRs, native Ad packaging/enhancer sequences (nt 218-354) which include repeat elements I-V, a repeat of Ad5 sequences 218-354, and the remaining native Ad packaging/enhancer sequences which include intact repeat elements VI and VII, or (b) Ad 5' ITRs, native Ad5 packaging/enhancer sequences (nt 186-371) which include repeat elements I-NI+, a repeat of Ad5 sequences 186-371, and the remaining native Ad packaging/enhancer sequences which includes an intact repeat element VII.
  • Ad 5' ITRs native Ad packaging/enhancer sequences (nt 218-354) which include repeat elements I-V, a repeat of Ad5 sequences 218-354, and the remaining native Ad packaging/enhancer sequences which include intact repeat elements VI and VII
  • Ad 5' ITRs native Ad5 packaging/enhancer sequences (nt 186-3
  • An adenoviral isolate was obtained which contains the 5' ITRs and a duplication of native Ad5 packaging domain elements I-V as described above.
  • a fragment containing the ITRs and duplicate packaging domains was obtained from the adenoviral isolate as an approximately 1 kb fragment after BamHI digestion and the fragment was cloned into pBluescript at an EcoRV - BamHI site.
  • the region corresponding to Ad5 map units (m.u.) 0-1 was removed from this new clone in a Pstl-HincII digestion, and the clone was filled-in with polymerase.
  • pAdLink (which contains native Ad5 mu 0-1, a polycloning site, and Ad5 m.u. 9-16) was digested with Nhel and EcoRV to remove native Ad5 m.u. 0- 1, and filled-in with polymerase. Subsequently, the clone containing Ad5 m.u. 0-1 with the duplicate packaging domains was inserted into the Nhel and EcoRV sites to create the modified pAdLink.
  • This modified pAdLink(I-V) now contains:
  • Ad5 m.u. 0-1 which include Ad 5' ITRs, native Ad packaging/enhancer sequences (nt 218-354) which include repeat elements I-V, a repeat of Ad5 sequences (nt 218-354), and the remaining native Ad packaging/enhancer sequences which include intact repeat elements VI and VII;
  • Ad5 m.u. 9-16 The deletion of the Ad5 m.u. between 1 and 9 corresponds to a deletion in the El region.
  • a minicassette containing the desired promoter, transgene sequences, and a polyA site was subcloned into the polycloning site of the modified pAdLink(I-V) vector.
  • a modified pAdLink was constructed essentially as described in Part A above, with the exception that the Ad5 map units 0-1 obtained from the viral isolate H5.001CBhOTC contain a duplication of native Ad5 packaging domain elements I- VI+ as described above.
  • the modified pAdLink(I-VI+) now contains:
  • Ad5 m.u. 0-1 which includes Ad 5' ITRs, native Ad5 packaging/enhancer sequences (nt 186-371) which include repeat elements I-VI+, a repeat of Ad5 sequences (nt 186-371) and the remaining native Ad packaging/enhancer sequences which include an intact repeat element VII;
  • Ad5 m.u. 9-16 The deletion of the Ad5 m.u. between 1 and 9 corresponds to a deletion in the El region.
  • a minicassette containing the desired promoter, transgene sequences, and a polyA site was subcloned into the polycloning site of the modified pAdLink(I-VI) vector.
  • the plasmid shuttle vector is derived from the modified pAdLink(I-V) described above.
  • a Sail site was introduced into a plasmid, pCMV ⁇ [Clontech, Palo Alto, CA] using known techniques that allow the isolation of the fragment of this plasmid which includes a minigene containing the CMV promoter/enhancer, the LacZ gene, and polyA site, which minigene is already bordered at one end by a Sail site.
  • the minigene was obtained from the modified pCMV ⁇ plasmid by Sail digestion, and cloned into the pAdLink(I-V) to create a plasmid shuttle vector useful for production of a recombinant adenovirus.
  • the plasmid shuttle vector contains from 5' to 3':
  • Ad5 m.u. 0-1 which include the Ad 5' ITRs, native Ad packaging/enhancer sequences (nt 218-354) which include repeat elements I-V, a repeat of Ad5 sequences (nt 218-354), and the remaining native Ad packaging/enhancer sequences which include intact repeat elements VI and VII;
  • a reporter minigene which contains a CMV promoter/enhancer which controls expression of the LacZ transgene, and a polyA sequence;
  • Ad5 m.u. 9-16 The deletion of the Ad5 m.u. between 1 and 9 corresponds to a deletion in the El region.
  • This plasmid shuttle vector is transfected into 293 cells (which express adenovirus proteins Ela and Elb) using conventional calcium phosphate techniques [B. Cullen, Meth. Enzy ol.. 152:684-704 (1987)], together with the Clal-restricted Ad5 backbone [ATCC], and cultured under standard conditions. Through homologous recombination, the vector is packaged into an Ad5 capsid to produce a recombinant adenovirus which contains elements (a) through (c) from the shuttle vector with a deletion in the El region.
  • the recombinant El -deleted adenovirus is obtained from cell pellet prepared using conventional techniques, e.g., sonication and freeze-thaw techniques, optionally followed by purification by cesium-chloride step gradient. Because of the advantage provided by the presence of multiple packaging domains, significantly higher yields of the recombinant adenovirus of the invention, as compared to the virus providing Ad5 backbone, are obtained.
  • Ad5 m.u. 0-1 which includes Ad 5' ITRs, native Ad5 packaging/enhancer sequences (nt 186-371) which include repeat elements I-VI+, a repeat of Ad5 sequences (nt 186-371) and the remaining native Ad packaging/enhancer sequences which include an intact repeat element VII;
  • a recombinant adenovirus is created in an El/E4-complementing cell through homologous recombination between a plasmid shuttle vector and a Clal-restricted Ad5 mutant viral backbone with a 1.9 kb deletion in the E4 region, dl 1004 [Bridge and G. Katner, J. Virol., 63_:6031-6038 (1989)].
  • the plasmid shuttle vector with duplicate repeat elements I-V contains from 5' to 3':
  • Ad5 m.u. 0-1 which include the Ad 5' ITRs, native Ad packaging/enhancer sequences (nt 218-354) which include repeat elements I-V, a repeat of Ad5 sequences (nt 218-354), and the remaining native Ad packaging/enhancer sequences which include intact repeat elements VI and VII;
  • a minigene which contains human ornithine transcarbamylase (OTC) expressed under the control of a CMV enhancer and chicken beta-actin promoter sequences, and a polyA sequence; and (c) Ad5 m.u. 9-16.
  • OTC human ornithine transcarbamylase
  • the plasmid shuttle vector is introduced into 84-31 cells (which express Ela, Elb and E4 protein) by calcium phosphate techniques, together with the dll004, and the cells are cultured under standard conditions. Through homologous recombination, the plasmid shuttle vector is packaged into an Ad5 capsid to produce a recombinant adenovirus which contains elements (a) through (c) from the shuttle vector, with a deletion in the El region ( ⁇ m.u. 1-9 ) and E4 region ( ⁇ m.u. -91.9 - 97.1).
  • a recombinant adenovirus is created in an El -complementing cell through homologous recombination between two plasmid shuttle vectors.
  • a first plasmid shuttle vector contains adenovirus sequences corresponding to adenovirus map units 0-16, which include the native 5' ITRs and the native Ad5 packaging/enhancer domain, and a second packaging domain which spans nt 240 - 346 of Ad [containing repeat elements I - V]. These sequences were cloned into a plasmid containing an intact E 1 region as a PCR fragment obtained from amplification of the native Ad5 repeat elements I -V.
  • a second plasmid shuttle vector contains the remaining required adenovirus sequences to permit packaging, with the exception of the El region (m.u. 1-9) which function is provided by the packaging cells.
  • This second plasmid shuttle vector therefore contains a minigene (which includes Ad m.u. 9-78.3, a reporter gene, LacZ, expressed under the control of CMV promoter/enhancer sequences, and a polyA sequence) inserted into the site of the E3-deletion (m.u. 78.3- m.u. 85.8), and Ad5 m.u.85.8 - 100.
  • the two plasmid shuttle vectors are transfected into 293 cells (which express Ela and Elb protein) and cultured under standard conditions. Through homologous recombination, a recombinant adenovirus which contains Ad5 m.u. 0-36, including the duplicate Ad packaging domains and a reporter minigene located in the site of the deletion in the E3 region ( ⁇ m.u. 78.3-85.8) is obtained.
  • the El-intact adenovirus is obtained from culture using conventional freeze-thaw techniques and subjected to purification by cesium-chloride gradient.
  • recombinant adenoviruses of the invention may be produced using other dual shuttle plasmid vector systems.
  • a first plasmid shuttle vector contains 5' ITRs, multiple packaging domains, and substantially all of the adenoviral gene, with the exception of the 3' ITRs.
  • the second plasmid shuttle vector provides an intact 3' ITR and sufficient adenoviral sequences to permit efficient homologous recombination, and lacks 5' ITRs, the packaging/enhancer region, and an intact El region.

Abstract

L'invention concerne un vecteur d'adénovirus de recombinaison possédant des domaines multiples d'encapsidation d'adénovirus. Ce vecteur présente des avantages par rapport à des vecteurs d'adénovirus classiques, étant donné qu'il permet d'encapsider des vecteurs de plasmides dans des capsides adénovirales. Elle concerne également des procédés de préparation et de d'utilisation de ce vecteur.
PCT/US2000/032235 1999-12-03 2000-11-27 Compositions et procedes servant a augmenter l'encapsidation et la production d'adenovirus de recombinaison au moyen de signaux multiples d'encapsidation WO2001040455A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001542523A JP2003523180A (ja) 1999-12-03 2000-11-27 多重のパッケージングシグナルを用いる組み換えアデノウイルスのパッケージングおよび収量を増加するための組成物および方法
CA002392537A CA2392537A1 (fr) 1999-12-03 2000-11-27 Compositions et procedes servant a augmenter l'encapsidation et la production d'adenovirus de recombinaison au moyen de signaux multiples d'encapsidation
AU17968/01A AU1796801A (en) 1999-12-03 2000-11-27 Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals
EP00980747A EP1234048A2 (fr) 1999-12-03 2000-11-27 Compositions et procedes servant a augmenter l'encapsidation et la production d'adenovirus de recombinaison au moyen de signaux multiples d'encapsidation
US10/169,544 US6821512B1 (en) 1999-12-03 2000-11-27 Compositions and methods for increasing packaging and yield of recombinant adenoviruses using multiple packaging signals
US10/996,341 US20070134203A1 (en) 1999-12-03 2004-11-23 Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16902599P 1999-12-03 1999-12-03
US60/169,025 1999-12-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/996,341 Continuation US20070134203A1 (en) 1999-12-03 2004-11-23 Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals

Publications (2)

Publication Number Publication Date
WO2001040455A2 true WO2001040455A2 (fr) 2001-06-07
WO2001040455A3 WO2001040455A3 (fr) 2002-01-17

Family

ID=22613973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032235 WO2001040455A2 (fr) 1999-12-03 2000-11-27 Compositions et procedes servant a augmenter l'encapsidation et la production d'adenovirus de recombinaison au moyen de signaux multiples d'encapsidation

Country Status (5)

Country Link
EP (1) EP1234048A2 (fr)
JP (1) JP2003523180A (fr)
AU (1) AU1796801A (fr)
CA (1) CA2392537A1 (fr)
WO (1) WO2001040455A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6806058B2 (en) 2001-05-26 2004-10-19 One Cell Systems, Inc. Secretions of proteins by encapsulated cells
US7198951B2 (en) 2001-12-17 2007-04-03 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US7282199B2 (en) 2001-12-17 2007-10-16 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US8524446B2 (en) 2001-11-13 2013-09-03 The Trustees Of The University Of Pennsylvania Method for detecting adeno-associated virus
US9890365B2 (en) 2014-03-09 2018-02-13 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053085A2 (fr) * 1998-04-15 1999-10-21 The Research Foundation Of State University Of New York Regulation selective de la production d'adenovirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053085A2 (fr) * 1998-04-15 1999-10-21 The Research Foundation Of State University Of New York Regulation selective de la production d'adenovirus

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GRABLE M ET AL: "CIS AND TRANS REQUIREMENTS FOR THE SELECTIVE PACKAGING OF ADENOVIRUS TYPE 5 DNA" JOURNAL OF VIROLOGY,US,NEW YORK, US, vol. 66, no. 2, 1 February 1992 (1992-02-01), pages 723-731, XP002012398 ISSN: 0022-538X *
HEHIR K M ET AL: "MOLECULAR CHARACTERIZATION OF REPLICATION-COMPETENT VARIANTS OF ADENOVIRUS VECTORS AND GENOME MODIFICATIONS TO PREVENT THEIR OCCURRENCE" JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 70, no. 12, December 1996 (1996-12), pages 8459-8467, XP002911790 ISSN: 0022-538X *
KOCHANEK S ET AL: "A NEW ADENOVIRAL VECTOR: REPLACEMENT OF ALL VIRAL CODING SEQUENCES WITH 28 KB OF DNA INDEPENDENTLY EXPRESSING BOTH FULL-LENGTH DYSTROPHIN AND BETA-GALACTOSIDASE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 93, 1 June 1996 (1996-06-01), pages 5731-5736, XP000652052 ISSN: 0027-8424 *
LANUTI, M. ET AL.: "Evaluation of an E1E4-delted adenovirus expressing the Herpes simplex thymidine kinase suicide gene in cancer gene therapy " HUMAN GENE THERAPY, vol. 10, 10 February 1999 (1999-02-10), pages 463-475, XP000995599 *
SANDIG, V. ET AL.: "Optimization of the helper-dependent adenovirus system for production and potency in vivo" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 3, 1 February 2000 (2000-02-01), pages 1002-1007, XP000985990 *
SCHMID S I AND HEARING P: "Bipartite structure and functional independence of adenovirus 5 packaging elements" JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 71, no. 5, May 1997 (1997-05), pages 3375-3384, XP002108134 ISSN: 0022-538X *
SCHMID S I ET AL: "Cellular components interact with adenovirus type 5 minimal DNA packaging domains" JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 72, no. 8, August 1998 (1998-08), pages 6339-6347, XP002117828 ISSN: 0022-538X *
SEGGERN VON D J ET AL: "A HELPER-INDEPENDENT ADENOVIRUS VECTOR WITH E1, E3, AND FIBER DELETED: STRUCTURE AND INFECTIVITY OF FIBERLESS PARTICLES" JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 73, no. 2, 1999, pages 1601-1608, XP000906914 ISSN: 0022-538X *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637255B2 (en) 1998-11-05 2014-01-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
US7105345B2 (en) 1998-11-05 2006-09-12 The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US7186552B2 (en) 1998-11-05 2007-03-06 The Trustees Of University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US9163260B2 (en) 1998-11-05 2015-10-20 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
US6806058B2 (en) 2001-05-26 2004-10-19 One Cell Systems, Inc. Secretions of proteins by encapsulated cells
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US9790472B2 (en) 2001-11-13 2017-10-17 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US10041090B2 (en) 2001-11-13 2018-08-07 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US8524446B2 (en) 2001-11-13 2013-09-03 The Trustees Of The University Of Pennsylvania Method for detecting adeno-associated virus
US11499167B2 (en) 2001-11-13 2022-11-15 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US8906675B2 (en) 2001-11-13 2014-12-09 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US11377669B2 (en) 2001-11-13 2022-07-05 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US11041171B2 (en) 2001-11-13 2021-06-22 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US11034977B2 (en) 2001-11-13 2021-06-15 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US11034976B2 (en) 2001-11-13 2021-06-15 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US10544432B2 (en) 2001-11-13 2020-01-28 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US10526617B2 (en) 2001-11-13 2020-01-07 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US10508286B2 (en) 2001-11-13 2019-12-17 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US10308958B2 (en) 2001-11-13 2019-06-04 The Trustees Of The University Of Pennsylvania Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
US10266846B2 (en) 2001-12-17 2019-04-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US8962332B2 (en) 2001-12-17 2015-02-24 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US8318480B2 (en) 2001-12-17 2012-11-27 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US10301650B2 (en) 2001-12-17 2019-05-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US7790449B2 (en) 2001-12-17 2010-09-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor
US7198951B2 (en) 2001-12-17 2007-04-03 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor
US9677089B2 (en) 2001-12-17 2017-06-13 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US9587250B2 (en) 2001-12-17 2017-03-07 Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US10590435B2 (en) 2001-12-17 2020-03-17 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US11396663B2 (en) 2001-12-17 2022-07-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US11390883B2 (en) 2001-12-17 2022-07-19 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US9493788B2 (en) 2001-12-17 2016-11-15 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US7282199B2 (en) 2001-12-17 2007-10-16 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US8962330B2 (en) 2001-12-17 2015-02-24 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US10167454B2 (en) 2014-03-09 2019-01-01 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
US10781430B2 (en) 2014-03-09 2020-09-22 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
US10626382B2 (en) 2014-03-09 2020-04-21 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
US9890365B2 (en) 2014-03-09 2018-02-13 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
US11732246B2 (en) 2014-03-09 2023-08-22 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency

Also Published As

Publication number Publication date
EP1234048A2 (fr) 2002-08-28
JP2003523180A (ja) 2003-08-05
AU1796801A (en) 2001-06-12
CA2392537A1 (fr) 2001-06-07
WO2001040455A3 (fr) 2002-01-17

Similar Documents

Publication Publication Date Title
EP1064393B1 (fr) Compositions et methodes de production de virus adeno-associes recombines sans auxiliaire
ES2552688T3 (es) Adenovirus de simio con proteínas de la cápside hexónica de SAdV-46 y usos del mismo
US20030092161A1 (en) Compositions and methods for production of recombinant viruses, and uses therefor
US7056502B2 (en) Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
US7115391B1 (en) Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
EP1163354B1 (fr) Compositions et techniques de production sans auxiliaire de virus adeno-associes de recombinaison
US6953690B1 (en) Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4693244B2 (ja) 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
JP4769417B2 (ja) アデノ随伴ウイルス（ａａｖ）血清型９の配列、それを含むベクターおよびその使用
ES2607029T3 (es) Adenovirus que comprende una proteína hexónica de la cápside del adenovirus E de simio SAdV-39 y usos de la misma
KR101614362B1 (ko) 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
US6793926B1 (en) Methods for production of a recombinant adeno-associated virus
AU2409200A (en) Compositions and methods useful for production of recombinant viruses which require helper viruses
US20030013189A1 (en) Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
US6821512B1 (en) Compositions and methods for increasing packaging and yield of recombinant adenoviruses using multiple packaging signals
WO2002070719A2 (fr) Systeme d'expression genique regulable
CA2385823A1 (fr) Production de virus associes a l'adenovirus (aav) recombinants mettant en oeuvre un adenovirus comprenant des genes rep/cap associes a l'adenovirus
EP1234048A2 (fr) Compositions et procedes servant a augmenter l'encapsidation et la production d'adenovirus de recombinaison au moyen de signaux multiples d'encapsidation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2392537

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 542523

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10169544

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000980747

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000980747

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642